Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Moonlake Immunotherapeutics (MLTX)

Moonlake Immunotherapeutics (MLTX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
44.27 +1.04 (+2.41%) 02/12/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 44.27 unch (unch) 17:04 ET
Quote Overview for Wed, Feb 12th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
42.40
Day High
44.39
Open 42.66
Previous Close 43.23 43.23
Volume 407,800 407,800
Avg Vol 485,180 485,180
Stochastic %K 20.72% 20.72%
Weighted Alpha -22.68 -22.68
5-Day Change -2.36 (-5.06%) -2.36 (-5.06%)
52-Week Range 37.55 - 64.00 37.55 - 64.00
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,762,613
  • Shares Outstanding, K 63,905
  • Annual Sales, $ 0 K
  • Annual Income, $ -36,010 K
  • EBIT $ -109 M
  • EBITDA $ -109 M
  • 60-Month Beta 1.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.68

Options Overview Details

View History
  • Implied Volatility 63.01% ( -3.75%)
  • Historical Volatility 51.44%
  • IV Percentile 54%
  • IV Rank 20.01%
  • IV High 126.85% on 02/13/24
  • IV Low 47.04% on 11/25/24
  • Put/Call Vol Ratio 0.25
  • Today's Volume 10
  • Volume Avg (30-Day) 113
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 2,966
  • Open Int (30-Day) 3,086

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.63
  • Number of Estimates 8
  • High Estimate -0.45
  • Low Estimate -0.76
  • Prior Year -0.12
  • Growth Rate Est. (year over year) -425.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.27 +7.27%
on 01/16/25
Period Open: 46.31
49.06 -9.76%
on 01/15/25
-2.04 (-4.42%)
since 01/10/25
3-Month
41.27 +7.27%
on 01/16/25
Period Open: 51.89
58.26 -24.01%
on 12/17/24
-7.62 (-14.68%)
since 11/12/24
52-Week
37.55 +17.90%
on 06/24/24
Period Open: 63.86
64.00 -30.83%
on 02/13/24
-19.59 (-30.68%)
since 02/12/24

Most Recent Stories

More News
Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely?

Oppenheimer has included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.

GURU : 53.29 (+0.16%)
GDOC : 33.87 (-0.01%)
SBIO : 32.08 (+1.23%)
MLTX : 44.27 (+2.41%)
Will this year's top performing stock ETFs stay hot in '24?

Even if there is a clear market rotation, these top performing ETFs will have an opportunity to secure gains and move on to be potential trophy winners in 2024.

ARKK : 62.68 (+2.17%)
FBCG.BZ : N/A (N/A)
VCAR : 23.85 (-1.81%)
COIN : 274.90 (+3.00%)
ROKU : 84.78 (+2.45%)
META : 725.38 (+0.78%)
PLTR : 117.39 (+4.24%)
SHOP : 120.49 (-2.51%)
NVDA : 131.14 (-1.25%)
UBER : 79.35 (+3.12%)
ANF : 108.91 (-0.47%)
DKNG : 45.44 (+4.60%)
Why Shares of MoonLake Immunotherapeutics Are Rising Tuesday

A competitor's clinical trial stumble may be benefiting MoonLake.

SLRN : 2.00 (-1.48%)
MLTX : 44.27 (+2.41%)
MarketBeat Week in Review – 6/26 - 6/30

Markets headed into a holiday week cheering a lower-than-expected key inflation reading, but investors should expect volatility in a short trading week.

NIO : 4.21 (+4.21%)
FROG : 36.93 (+2.73%)
MLTX : 44.27 (+2.41%)
MDB : 292.46 (+2.22%)
SHW : 355.50 (-1.62%)
GIS : 58.44 (-1.53%)
MULN : 0.3040 (+18.06%)
AAPL : 236.87 (+1.83%)
GOOGL : 183.61 (-0.92%)
LCID : 2.87 (+6.69%)
KFY : 66.39 (-2.63%)
META : 725.38 (+0.78%)
Why MoonLake Immunotherapeutics Stock Skyrocketed This Week

Positive mid-stage results fueled a spike in the biotech's shares this week.

MLTX : 44.27 (+2.41%)
MoonLake Immunotherapeutics Makes a Moonshot on Trials

Clinical-stage biotech MoonLake Immunotherapeutics AG (NASDAQ: MLTX) shares spiked 70% on positive clinical trial results.

MLTX : 44.27 (+2.41%)
IMGN : 31.23 (unch)
Why MoonLake Immunotherapeutics Was Such a Healthy Stock Today

The heavily bullish sentiment on the company only grew on the second trading day of the week.

BCS : 15.39 (+1.05%)
MLTX : 44.27 (+2.41%)
Why Shares of MoonLake Immunotherapeutics Skyrocketed Monday

The company reported positive phase 2 clinical trial results.

MLTX : 44.27 (+2.41%)
MoonLake Immunotherapeutics (NASDAQ: MLTX) Announces Breakthrough Results for Sonelokimab in Phase 2 Trial

MoonLake Immunotherapeutics (NASDAQ: MLTX) has made significant strides with the successful outcome of their Phase 2 MIRA trial for sonelokimab,

MLTX : 44.27 (+2.41%)
Lucid Stock Moved Into the Fast Lane, but This Nasdaq Biotech Was Monday's Big Winner

Markets looked poised to start the new week flat.

COMP : 7.50 (+0.81%)
$NASX : 19,649.95 (+0.03%)
LCID : 2.87 (+6.69%)
MLTX : 44.27 (+2.41%)
Stocks Set to Open Lower as Investors Await Key U.S. Inflation Data, Powell Speech

September S&P 500 futures (ESU23) are down -0.12%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.22% this morning as market participants looked ahead to the release of the Fed’s favorite...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
TSLA : 336.51 (+2.44%)
NVDA : 131.14 (-1.25%)
JD : 39.31 (-3.65%)
PDD : 118.83 (+1.15%)
KMX : 86.44 (-0.30%)
DBK.D.DX : 19.170 (+2.07%)
AML.LN : 113.400 (+0.89%)
MLTX : 44.27 (+2.41%)
ETNB : 11.01 (-1.52%)
GOOGL : 183.61 (-0.92%)
Chart of the Day: MoonLake Immunotherapeutics - Undiscovered

The Chart of the Day belongs to the under covered stock MoonLake Immunotherapeutics (MLTX) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical...

MLTX : 44.27 (+2.41%)
MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH

MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH ZUG, Switzerland, July 26, 2022 – MoonLake...

MLTX : 44.27 (+2.41%)
Why MoonLake Immunotherapeutics Stock Shot Up 41.1% on Tuesday

Shares of clinical-stage biotech stock rose nearly $3 a share from Friday's close.

MLTX : 44.27 (+2.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

MoonLake Immunotherapeutics AG is a clinical-stage biotechnology company. It focused on creating next-level therapies for inflammatory skin and joint diseases. MoonLake Immunotherapeutics AG, formerly known as Helix Acquisition Corp., is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 46.96
2nd Resistance Point 45.68
1st Resistance Point 44.97
Last Price 44.27
1st Support Level 42.98
2nd Support Level 41.70
3rd Support Level 40.99

See More

52-Week High 64.00
Fibonacci 61.8% 53.90
Fibonacci 50% 50.78
Fibonacci 38.2% 47.65
Last Price 44.27
52-Week Low 37.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Increase Profitable Opportunities with Barchart's Technical Opinion